Disclaimers

Please read before using anything on this site.

Educational use only

All content on ModernPeptideScience is for educational and informational purposes only. It is not medical advice, not a diagnosis, and not a treatment recommendation. Reading this site does not establish any patient-clinician relationship.

Decisions about whether to use, avoid, start, stop, or modify any peptide therapy, medication, or related intervention should be made in consultation with a qualified healthcare professional familiar with your specific clinical situation. Do not rely on this site as a substitute for that consultation.

No dosing or usage instructions

We describe how peptides are administered as reported in peer-reviewed studies, because that is part of characterizing the research. We do not provide protocols, "cycles," titration schedules for personal use, or sourcing guidance. Such use-oriented content is outside our scope.

Where community protocols are discussed (e.g., in articles about dosing practices), we describe what circulates in user communities for educational purposes — not as recommendations for personal use. The framing should be read as "this is what's discussed" rather than "this is what we recommend."

Regulatory and legal status

Most peptides discussed on this site are not FDA-approved for the applications most commonly discussed in the peptide community. The regulatory landscape has evolved substantially in recent years:

In 2023, the FDA placed many commonly-discussed peptides (BPC-157, TB-500, others) on Category 2 of the 503A bulk drug substances list, restricting compounding pharmacies' ability to prepare them under §503A.
In 2024-2025, the FDA declared the GLP-1 shortage (semaglutide, tirzepatide) resolved, closing most compounding pathways that had operated under shortage rules.
Approved peptide indications continue to expand — semaglutide gained obesity-CVD risk reduction labeling via SELECT; the obesity pharmacology pipeline is producing new approvals regularly.

Nothing on this site should be interpreted as advice about whether it is legal for you, in your jurisdiction, to purchase or possess any peptide. Those are questions for a qualified attorney. The legal landscape varies substantially by country, state, and intended use.

Safety

Many peptides have incomplete long-term safety data. Some peptides have documented serious risks:

GLP-1 medications: pancreatitis (uncommon but documented), gallbladder events with rapid weight loss, hypoglycemia in patients on insulin or sulfonylureas, medullary thyroid carcinoma warning based on rodent data.
Growth hormone axis (CJC-1295, IGF-1 LR3, tesamorelin): sustained IGF-1 elevation has epidemiologic association with cancer risk; glucose intolerance with chronic use; carpal tunnel-like symptoms; cardiac considerations.
Melanotan-II: skin malignancy signals; severe nausea; spontaneous erections; off-label use carries documented risks not present in FDA-approved melanocortin agonists like afamelanotide.
Myostatin-pathway compounds (YK-11, follistatin): hepatotoxicity case reports; uncharacterized long-term effects.
Research-grade peptides broadly: identity, purity, endotoxin contamination, and source-quality concerns documented in independent testing.

Decisions about use require a qualified healthcare professional who can evaluate your specific situation, baseline health status, current medications, and personal risk profile.

Editorial framing of compounds we cover

Inclusion of a peptide or compound on this site is descriptive, not a recommendation to use it. Our pages summarize what the published research shows; they do not endorse any specific vendor, compounding pharmacy, or retailer for sourcing decisions. Sourcing and access questions involve regulatory, quality, and clinical considerations that are appropriately handled with a qualified clinician familiar with your jurisdiction and situation.

The site does not currently accept advertising from peptide vendors or manufacturers, does not participate in affiliate-link arrangements with research peptide retailers, and does not include sponsored content in its editorial pages. If these positions change in the future, the changes will be disclosed transparently at the affected content so readers can evaluate the editorial alongside that context.

External links

Many pages on this site link to external resources — PubMed-indexed research articles, FDA regulatory documents, manufacturer press releases, and other research databases. These links are provided for evidence transparency and reader convenience. We do not control the content of external sites and are not responsible for their accuracy, availability, or any subsequent changes after we cite them.

External links are not endorsements. Citing a research paper does not constitute endorsement of the researchers, journal, or institution. Linking to a regulatory document does not constitute endorsement of the regulatory position. Linking to manufacturer information does not constitute endorsement of the manufacturer or product.

Newsletter and email

The site offers an optional newsletter signup powered by MailerLite. Signing up shares your email address with MailerLite for the purpose of delivering the newsletter. We do not sell, rent, or share email addresses with third parties. You can unsubscribe at any time using the unsubscribe link in any newsletter email.

For details on data collection and use, see our Privacy Policy.

Accuracy and corrections

We try to be accurate, but the field moves quickly and mistakes are possible. If you believe any statement on this site is incorrect, please reach out — corrections are treated seriously, tracked, and reflected in updated content.

To report a correction or factual concern, email info@modernpeptidescience.com with the URL, the specific claim in question, and (if possible) the source you believe should be cited instead.

Jurisdictional note

This site is operated from the United States. Regulatory framing, drug approval references, and legal context throughout the site default to U.S. context. Readers in other jurisdictions should consult local sources for region-specific regulatory, legal, and clinical information. Many peptides discussed have different approval status, availability, and legal context in different countries.

Changes to these disclaimers

We may update these disclaimers from time to time to reflect changes in the regulatory landscape, our editorial practices, or related considerations. Material changes will be reflected in the page's last-updated date. Continued use of the site after changes constitutes acceptance of the updated disclaimers.